{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:54:16Z","timestamp":1770886456962,"version":"3.50.1"},"reference-count":62,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"publisher","award":["ECDC\/2015\/028"],"award-info":[{"award-number":["ECDC\/2015\/028"]}],"id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Hepatitis C prevalence in prison populations is much higher than in the community. Effective hepatitis C treatment within this population does not only have a direct individual health benefit, but may lead to substantial community dividend. We reviewed available evidence on hepatitis C treatment in prison settings, with a focus on the European Union\/European Economic Area. A systematic review of the literature (PubMed, <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>, Cochrane library) was performed and complemented with searches for conference abstracts and grey literature. Thirty\u2010four publications were included reporting on the effectiveness, acceptability and economic aspects of hepatitis C virus treatment models of care to achieve treatment completion and sustained viral response in prison settings. Available evidence shows that hepatitis C treatment in prison settings is feasible and the introduction of direct\u2010acting antivirals will most likely result in increased treatment completion and better clinical outcomes for the prison population, given the caveats of affordability and the need for increased funding for prison health, with the resulting benefits accruing mostly in the community.<\/jats:p>","DOI":"10.1111\/jvh.12998","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T02:39:21Z","timestamp":1536201561000},"page":"1406-1422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the <scp>EU<\/scp>\/<scp>EEA<\/scp>"],"prefix":"10.1111","volume":"25","author":[{"given":"Hilde","family":"Vroling","sequence":"first","affiliation":[{"name":"Pallas Health Research and Consultancy B.V.  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk M.","family":"Oordt\u2010Speets","sequence":"additional","affiliation":[{"name":"Pallas Health Research and Consultancy B.V.  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Department of Clinical and Experimental Medicine University of Sassari  Sassari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Babudieri","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases Department of Clinical and Experimental Medicine University of Sassari  Sassari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Monarca","sequence":"additional","affiliation":[{"name":"Health Without Barriers \u2010 European Federation for Prison Health  Viterbo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eamonn","family":"O'Moore","sequence":"additional","affiliation":[{"name":"Public Health England, Health and Justice  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marije","family":"Vonk Noordegraaf\u2010Schouten","sequence":"additional","affiliation":[{"name":"Pallas Health Research and Consultancy B.V.  Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wolff","sequence":"additional","affiliation":[{"name":"Division of Prison Health Geneva University Hospitals and University of Geneva  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialinda","family":"Montanari","sequence":"additional","affiliation":[{"name":"European Monitoring Centre on Drugs and Drug Addiction  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Hedrich","sequence":"additional","affiliation":[{"name":"European Monitoring Centre on Drugs and Drug Addiction  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2217-4664","authenticated-orcid":false,"given":"Lara","family":"Tavoschi","sequence":"additional","affiliation":[{"name":"European Centre for Disease Prevention and Control  Stockholm Sweden"},{"name":"Department of Translational Research and New technologies in Medicine and Surgery University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"SPACE I \u2013 Council of Europe Annual Penal Statistics: Prison Populations Survey 2014","author":"Aebi M","year":"2015"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30466-4"},{"key":"e_1_2_9_4_1","volume-title":"Systematic Review on Hepatitis B and C Prevalence in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2016"},{"key":"e_1_2_9_5_1","volume-title":"Hepatitis C Among Drug Users in Europe: Epidemiology, Treatment and Prevention, EMCDDA Insights 23","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2016"},{"key":"e_1_2_9_6_1","volume-title":"European Drug Report 2017: Trends and Developments","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017"},{"key":"e_1_2_9_7_1","volume-title":"Drug Use in Prisoners","author":"Kinner SA","year":"2018"},{"key":"e_1_2_9_8_1","volume-title":"European Monitoring Centre for Drugs and Drug Addiction Prisons and Drugs in Europe: The Problem and Responses Lisbon","author":"EMCDDA","year":"2012"},{"key":"e_1_2_9_9_1","volume-title":"Prisons and Health","author":"World Health Organization","year":"2014"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30769-3"},{"key":"e_1_2_9_11_1","unstructured":"StoneJ HickmanM LimA et\u00a0al.Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: A systematic review and meta\u2010analysis. Presented at the 4th International HIV\/Viral Hepatitis Co\u2010Infection Meeting; 22\u201023 July2017; Paris Francehttps:\/\/iasociety.org\/Co-Infections\/Hepatitis."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxx014"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxy002"},{"key":"e_1_2_9_14_1","volume-title":"Action Plan for the Health Sector Response to Viral Hepatitis in the WHO European Region","author":"World Health Organization","year":"2016"},{"key":"e_1_2_9_15_1","volume-title":"Health and Social Responses to Drug Problems: A European Guide","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0617"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13783"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22509"},{"key":"e_1_2_9_19_1","volume-title":"Global Health Sector Strategy on HIV, 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"e_1_2_9_20_1","unstructured":"European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; in press.http:\/\/www.easl.eu\/medias\/cpg\/2018\/EASL%20Recommendations%20on%20Treatment%20of%20Hepatitis%20C%202018\/English-report.pdf"},{"key":"e_1_2_9_21_1","unstructured":"World Health Organization.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Updated version. April 2016.Geneva Switzerland:WHO 2016."},{"key":"e_1_2_9_22_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2011"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"e_1_2_9_24_1","unstructured":"National Institute for Health and Care Excellence.The guidelines manual 2012 [updated 30 November 2012.https:\/\/www.nice.org.uk\/process\/pmg6\/resources\/the-guidelines-manual-appendices-bi-2549703709\/chapter\/appendix-b-methodology-checklist-systematic-reviews-and-meta-analyses"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-3-200302040-00010"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12580"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06295.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2010.tb03605.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31818dd94c"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000163"},{"issue":"2","key":"e_1_2_9_31_1","first-page":"44","article-title":"Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study","volume":"13","author":"de Juan J","year":"2011","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2004.056150"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/767540"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-374"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0602"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1202"},{"issue":"4","key":"e_1_2_9_37_1","first-page":"423","article-title":"Predictors of adherence to treatment of chronic hepatitis C in drug\u2010dependent inmate patients in four prisons in Barcelona, Spain","volume":"84","author":"Marco Mourino A","year":"2010","journal-title":"Revista espanola de salud publica"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/591707"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25770"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2014.03.004"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2298\/MPNS1604085S"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40116.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30310.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0483-8"},{"key":"e_1_2_9_45_1","first-page":"99","article-title":"Tratamiento con SofosbuvirLedipasvir en poblaci\u00f3n penitenciaria espa\u00f1ola con Hepatitis cr\u00f3nica C","volume":"18","author":"Fern\u00e1ndez\u2010Gonz\u00e1lez F","year":"2016","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_46_1","first-page":"92","article-title":"Efectividad y seguridad del tratamiento con antivirales de acci\u00f3n directa (AAD) y su impacto en la rigidez hep\u00e1tica en pacientes con hepatitis cr\u00f3nica VHC. Experiencia en un Centro Penitenciario","volume":"18","author":"Jim\u00e9nez\u2010Gal\u00e1n G","year":"2016","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_47_1","first-page":"89","article-title":"Tasa y causas de discontinuaci\u00f3n del tratamiento con Interfer\u00f3n Pegilado (INFpeg) m\u00e1s Ribavirina (RBV) en presos tratados de HCC en Catalu\u00f1a durante 2002\u20102008","volume":"12","author":"Marco A","year":"2010","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_48_1","first-page":"100","article-title":"Respuesta virol\u00f3gica r\u00e1pida extendida en presos espa\u00f1oles con y sin infecci\u00f3n por vih tratados de la hepatitis cr\u00f3nica C con Telaprevir, Peginterferon Alfa y Ribavirina","volume":"16","author":"Marco A","year":"2014","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_49_1","first-page":"101","article-title":"18 meses de tratamiento con Telaprevir o Boceprevir m\u00e1s Interferon Pegilado y Ribavirina en presos de Catalu\u00f1a. Resultados preliminares de eficacia y de discontinuaci\u00f3n de tratamiento","volume":"16","author":"Marco A","year":"2014","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_50_1","first-page":"88","article-title":"Interrupci\u00f3n del tratamiento de la hepatitis C cr\u00f3nica con antivirales de acci\u00f3n directa por causas de origen penitenciario en las prisiones de Catalu\u00f1a","volume":"18","author":"Marco Mourino A","year":"2016","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_51_1","unstructured":"MerouehF.HCV elimination in prison is feasible: a French experience.2017(unpublished)."},{"key":"e_1_2_9_52_1","first-page":"96","article-title":"Eficacia de las terapias libres de interfer\u00f3n frente al VHC en el medio penitenciario","volume":"18","author":"M\u00ednguez\u2010Gallego C","year":"2016","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_53_1","first-page":"102","article-title":"Respuesta al tratamiento de la hepatitis cr\u00f3nica C en una poblaci\u00f3n de usuarios de metadona","volume":"12","author":"Pall\u00e1s J","year":"2010","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_54_1","unstructured":"PontaliE.Treatment with DAAs in a multicenter cohort of HCV\u2010infected prisoners in Italy.2017."},{"key":"e_1_2_9_55_1","first-page":"94","article-title":"Estudio comparativo de la eficacia en poblaci\u00f3n presa con hepatitis cr\u00f3nica C del tratamiento directamente observado de Ribavirina vs autoadministrado, ambos con Interfer\u00f3n Pegilado alfa2a directamente observado (ensayo cl\u00ednico Ribadot)","volume":"12","author":"Saiz de la Hoya P","year":"2010","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_56_1","first-page":"87","article-title":"Eficacia, seguridad y discontinuaci\u00f3n del tratamiento de la Hepatitis C Cr\u00f3nica con antivirales de acci\u00f3n directa en las prisiones de Catalu\u00f1a","volume":"18","author":"Touz\u00f3n\u2010L\u00f3pez C","year":"2016","journal-title":"Revista espanola de sanidad penitenciaria"},{"key":"e_1_2_9_57_1","volume-title":"HCV Treatment in Pierre Nicole Center\/Inserm U1018","author":"Michel L","year":"2017"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.05.019"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003004"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30284-4"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28497"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.033"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:05:40Z","timestamp":1694808340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/jvh.12998"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12998","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"2018-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}